Vera Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Vera Therapeutics, Inc. (VERA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $4.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-10
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $4.30M, a 330.00% increase year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $4.40M, a 57.14% increase year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $8.20M, a 32.23% decline year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $100.00K, a 97.14% decline year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $12.00M, a 74.36% decline from fiscal 2024.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $46.80M, a 4580.00% increase from fiscal 2023.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.00M, a 82.76% decline from fiscal 2022.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $5.80M, a 2800.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.30M 10-Q · filed 2026-08-10 | $8.70M 10-Q · filed 2026-08-10 | $16.90M derived: sum of 3 quarters · filed 2026-08-10 | $17.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.40M 10-Q · filed 2026-05-07 | $12.60M derived: sum of 2 quarters · filed 2026-05-07 | $12.70M derived: sum of 3 quarters · filed 2026-05-07 | $13.70M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.30M derived: sum of 2 quarters · filed 2026-02-26 | $9.30M derived: sum of 3 quarters · filed 2026-08-10 | $12.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-05 | $1.10M derived: sum of 2 quarters · filed 2026-08-10 | $3.80M 10-Q · filed 2025-11-05 | $16.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-10 | $3.70M 10-Q · filed 2026-08-10 | $15.90M derived: sum of 3 quarters · filed 2026-08-10 | $19.40M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.80M 10-Q · filed 2026-05-07 | $14.90M derived: sum of 2 quarters · filed 2026-05-07 | $18.40M derived: sum of 3 quarters · filed 2026-05-07 | $29.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.60M derived: sum of 2 quarters · filed 2026-02-26 | $26.20M derived: sum of 3 quarters · filed 2026-02-26 | $46.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.50M 10-Q · filed 2025-11-05 | $14.10M derived: sum of 2 quarters · filed 2025-11-05 | $34.70M 10-Q · filed 2025-11-05 | $34.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $10.60M 10-Q · filed 2025-08-05 | $31.20M 10-Q · filed 2025-08-05 | $31.30M derived: sum of 3 quarters · filed 2026-02-26 | $31.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $20.50M 10-Q · filed 2025-05-07 | $20.70M derived: sum of 2 quarters · filed 2026-02-26 | $21.30M derived: sum of 3 quarters · filed 2026-02-26 | $21.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $800.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.00M derived: sum of 3 quarters · filed 2026-02-26 | $1.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $600.00K 10-Q · filed 2023-11-09 | $800.00K derived: sum of 2 quarters · filed 2023-11-09 | $800.00K 10-Q · filed 2023-11-09 | $6.10M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $200.00K 10-Q · filed 2023-08-10 | $200.00K 10-Q · filed 2023-08-10 | $5.50M derived: sum of 3 quarters · filed 2023-08-10 | $8.60M derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $3.00M 10-Q · filed 2023-05-11 | $5.30M derived: sum of 2 quarters · filed 2023-05-11 | $8.40M derived: sum of 3 quarters · filed 2023-05-11 | $8.50M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $5.40M derived: sum of 2 quarters · filed 2023-03-28 | $5.50M derived: sum of 3 quarters · filed 2023-03-28 | $5.80M 10-K · filed 2023-03-28 |
| 2022-09-30 | $3.10M 10-Q · filed 2022-11-09 | $3.20M derived: sum of 2 quarters · filed 2022-11-09 | $3.50M 10-Q · filed 2022-11-09 | $3.49M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-10 | $400.00K 10-Q · filed 2022-08-10 | $394.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2022-03-31 | $300.00K 10-Q · filed 2022-05-16 | $294.00K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2021-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $200.00K 10-K · filed 2022-03-28 | ||
| 2021-09-30 | $206.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |